Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the target of a large drop in short interest in December. As of December 15th, there was short interest totaling 24,933 shares, a drop of 15.6% from the November 30th total of 29,530 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily volume of 61,206 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 61,206 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.8% of the company’s stock are sold short.

Institutional Trading of Scinai Immunotherapeutics

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC grew its stake in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,630 shares of the company’s stock after purchasing an additional 17,031 shares during the period. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. 58.41% of the stock is owned by institutional investors and hedge funds.

Scinai Immunotherapeutics Stock Up 10.0%

Shares of SCNI stock opened at $0.72 on Wednesday. Scinai Immunotherapeutics has a 12 month low of $0.61 and a 12 month high of $6.18. The firm has a market cap of $2.29 million, a PE ratio of -0.07 and a beta of 1.67. The stock has a 50 day moving average of $1.05 and a 200-day moving average of $1.51.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.